Aubagio approved for multiple sclerosis

(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

MS is a that affects communication between the brain and other parts of the body. About twice as prevalent in women than men, it's among the most common causes of in young adults, the FDA said in a news release.

The drug's label contains the FDA's most stringent black box warning, alerting doctors and patients to the possibility of deadly . Doctors are advised to perform blood tests of liver function before and during treatment, the agency said.

Aubagio's label also advises that the drug could harm a developing fetus. So, women of childbearing age must have a negative pregnancy test before beginning treatment and take effective birth control during treatment, the FDA said.

More common but less severe adverse reactions to the drug have included diarrhea, nausea and hair loss.

Aubagio, which is taken as a tablet once a day, is produced by Sanofi Aventis, based in Bridgewater, N.J.

More information: Medline Plus has more about multiple sclerosis.

add to favorites email to friend print save as pdf

Related Stories

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

New drug approved for irritable bowel, chronic constipation

Aug 30, 2012

(HealthDay)—Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome accompanied by ...

FDA clears safety test to screen Tysabri patients

Jan 20, 2012

(AP) -- The Food and Drug Administration on Friday approved a new diagnostic test to help identify patients who have an increased risk of developing a rare brain infection while taking Biogen Idec's multiple sclerosis drug ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments